Navigation Links
Isis Pharmaceuticals to Present at the 2013 UBS Global Healthcare Conference
Date:5/13/2013

CARLSBAD, Calif., May 13, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 2013 UBS Global Healthcare Conference on Monday, May 20, 2013 at 9:00 a.m. ET in New York, NY.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay will be available on the Isis Web site within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Genzyme is also pursuing marketing approval of KYNAMRO in other markets.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

Forward-Looking Statements

This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014  Decision Resources Group finds that the market for ... billion by 2023 in the United States ... , Italy , Spain ... Japan . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin ... by the launch of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, ...
(Date:8/28/2014)... , Aug. 28, 2014 Levi & ... commenced in the United States District Court for the ... of investors who purchased Galectin Therapeutics Inc. ("Galectin" or ... and July 28, 2014. For more information, ... alleges that during the Class Period the Company violated ...
(Date:8/28/2014)... , Aug. 28, 2014 Nonin Medical, ... leader in noninvasive medical monitoring, today announced that the ... Model 3231 OEM/eHealth finger pulse oximeter for use in ... pulse oximeter plugs into a telemedicine hub or kiosk ... pulse rate in pediatric to adult patients. The Model ...
Breaking Medicine Technology:The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... to Produce Therapeutic Proteins at Tumor,Site, ARLINGTON ... surgeons have delivered cancer fighting proteins through,skin flaps ... 79 percent reduction,in tumor volume, according to a ... Surgery(R), the official medical journal of the American,Society ...
... today announced the submission of a supplemental New ... Administration (FDA) for SEROQUEL XR(TM),(quetiapine fumarate) Extended-Release Tablets ... disorder (GAD), including maintenance of,antianxiety effect. It is ... an,atypical antipsychotic medicine in GAD. The submission is ...
Cached Medicine Technology:Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 2Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8
(Date:8/28/2014)... 2014 Valero Renewable Fuels Company, LLC, ... VLO), and the Ports of Indiana hosted Lt. Gov. ... at a Port Appreciation and Welcome Celebration commemorating the ... , “The opening of Valero’s ethanol facility at the ... development win for the State of Indiana,” Ellspermann said. ...
(Date:8/28/2014)... HealthDay Reporter THURSDAY, Aug. ... electrical currents through the scalp to a specific network of ... day. In a small study of healthy young adults, ... networks involved in memory. That, in turn, boosted participants, performance ... the brain stimulation. During TMS, an electromagnetic coil is ...
(Date:8/28/2014)... IL (PRWEB) August 28, 2014 Data ... Supplement shows that while most hospitals utilize a basic ... health care information technology is still a challenge. ... the August issue of Health Affairs , and ... Forum’s Health Care Data Center, as well as Chantal ...
(Date:8/28/2014)... is hurting reproduction of the endangered Devils Hole pupfish, threatening ... few as 35 individuals, new research by the University of ... that geothermal water on a small shelf near the surface ... pupfish live is heating up as a result of climate ... , The hotter water, which now reaches more than ...
(Date:8/28/2014)... 28, 2014 Dr. Paul Kovatis is being ... the U.S. military for his efforts to treat many wounded ... Warriors Foundation and several other military organizations. Dr. Kovatis’ ... in WWII. Having five members of his immediate family ... Cemetery, it’s no wonder Dr. Kovatis is so dedicated to ...
Breaking Medicine News(10 mins):Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 2Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 3Health News:Electrical Pulses to Scalp May Boost Memory: Study 2Health News:Electrical Pulses to Scalp May Boost Memory: Study 3Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 2Health News:AHA Data Shows Progress, Challenges on Road to Healthcare IT Adoption 3Health News:Climate change puts endangered Devils Hole pupfish at risk of extinction 2Health News:Climate change puts endangered Devils Hole pupfish at risk of extinction 3Health News:NJ Top Docs Presents, Dr. Paul Kovatis 2
... survey reveals that 61% of Australians are not aware of the ... the Salvation Army survey, binge drinking was "worryingly high" among teenage ... 41 % of the18 to 24-year-olds confessed to take not less ... ,"What is of such concern is that people don't know ...
... New York: An investigation into the degree of consequence type ... the condition before 50 years//, led to the finding that ... say Swedish researchers. ,The status of type ... measured with the presence of biological identification in the blood ...
... well known that the output of nerve cells is the ... is still unclear about how widely separated regions of the ... complex activity. A new study by neuroscientists at the University ... Francisco (UCSF) is getting to resolve this mystery. ...
... the degree of hangover one might experience, after a night ... delved into this arena, and studied the connection between the ... by being hangover less as compared to the ones with ... a hangover, characterized by an unbearable headache, nausea, dry mouth ...
... type 1 Diabetes was admitted to the Clinical Research Center ... // Four days later the North Shore suburban girl was ... body and ready to spend a few days at the ... to do well, her insulin was reduced day by day. ...
... would benefit a lot if they were given albumin ... in London and experts in Kenya have developed this ... with malaria. ,In initial studies less ... new treatment died, researchers said. "The observation is that ...
Cached Medicine News:Health News:The need for cancer warnings on alcohol packaging 2Health News:Slow brain waves integral in coordination of complex activity 2Health News:Molecular Medicine And Diabetes 2Health News:Molecular Medicine And Diabetes 3Health News:Molecular Medicine And Diabetes 4Health News:Molecular Medicine And Diabetes 5Health News:Molecular Medicine And Diabetes 6Health News:Molecular Medicine And Diabetes 7
The Biopro All Poly cup is a uniquely designed UHMWPE acetabular cup....
The Pe-Plus offers an additional clinical option for replacing the acetabulum....
BatCup cotyloid implant, designed for use in revision surgery, is an hemispherical metal cup, with grooves on the edges that house locking flanges, which are attached to the iliac bone by cancellous ...
The cementless acetabular shells form part of the Mallory head range of femoral and acetabular implants....
Medicine Products: